Vedolizumab-5050: Clinical Perspective of Vedolizumab (Entyvio) use in the Drug Program "Vedolizumab in the Treatment of Ulcerative Colitis" (POLONEZ)

First published 20/04/2020

Last updated 24/06/2022

EU PAS number:

EUPAS34119

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

Vedolizumab-5050_Protocol_redacted

English (1.36 MB - PDF)View document

Study results

Study results

Vedolizumab-5050_RDS_2022-06-14

English (687.3 KB - PDF)View document

Study report

Other information